Innovation
into.blood
Developing
therapies.for
the.treatment
of.rare.diseases
Developing and commercializing specialized therapies for the treatment of rare diseases by using the patient’s own blood
Latest News
View allEryDel Provides Regulatory Update on EryDex for the Treatment of Ataxia ...
February 22, 2023
Read moreEryDel to Present its Phase 3 Study Results for Ataxia Telangiectasia ...
April 05, 2022
Read more
Our Technology
EryDel’s proprietary platform technology is an easy to use, fast and automatic bedside procedure, to encapsulate small and large molecules including therapeutic enzymes in patients’ red blood cells. The cells are immediately re-infused into patients providing prolonged half-life in circulation, reduced immunogenicity, better tolerability and predictable vascular distribution.
DiscoverA late Stage
and Broad Pipeline

